According to the Societe Generale Securities Research Report, a number of major biosimilar drugs under Fuhong Hanlin-B (2696.HK) have been listed one after another; the company's product reserves are abundant, and combination therapies are poised for development. Currently, a number of innovative monoclonal and dual antibody drugs are in the development stage. The company's revenue for 2020-2022 is forecast to be $917, 21.01 and 3,915 million, respectively, up 908.41%, 129.14% and 86.35% over the previous year. With the continuous advancement of the company's R&D projects and the implementation of product sales, it is believed that the company is expected to experience an increase in valuation. Currently, the company is given a target price of HK$68.50, giving it a “buy” rating.